In a study, the clinical outcomes of patients with relapsed or refractory FLT3‐mutated AML in the CHRYSALIS and ADMIRAL trials were retrospectively compared to those of patients who had not previously received FLT3 TKI exposure and had received midostaurin or sorafenib. Here, FLT3 is linked to acute myeloid leukemia.